mRNA accessible site tagging (MAST): a novel high throughput method for selecting effective antisense oligonucleotides

被引:29
作者
Zhang, HY
Mao, JP
Zhou, DX
Xu, YH
Thonberg, H
Liang, ZC [1 ]
Wahlestedt, C
机构
[1] Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden
[2] United Biotechnol AB, S-17446 Sundbyberg, Sweden
关键词
D O I
10.1093/nar/gng072
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A solution-based method, mRNA accessible site tagging (MAST), has been developed to map the accessible sites of any given mRNA in high throughput fashion. mRNA molecules were immobilized and hybridized to randomized oligonucleotide libraries. Oligonucleotides specifically hybridized to the mRNA were sequenced and found to be able to precisely define the accessible sites of the mRNA. A number of ways were used to validate the accessible sites defined by the MAST process. Mapping of rabbit beta-globin mRNA demonstrates the efficacy and advantage of MAST over other technologies in identifying accessible sites. Antisense oligonucleotides designed according to the accessible site map of human RhoA and Renilla luciferase mRNA result in knockdown effects that are in good correlation with the degrees of accessibility. The MAST methodology can be applied to mRNA of any length using a universal protocol.
引用
收藏
页数:9
相关论文
共 16 条
  • [1] Antisense therapeutics
    Agrawal, S
    Zhao, QY
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) : 519 - 528
  • [2] Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase
    Allawi, HT
    Dong, F
    Ip, HS
    Neri, BP
    Lyamichev, VI
    [J]. RNA, 2001, 7 (02) : 314 - 327
  • [3] Bennett CF, 1999, CURR OPIN MOL THER, V1, P359
  • [4] Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design
    Braasch, DA
    Liu, YH
    Corey, DR
    [J]. NUCLEIC ACIDS RESEARCH, 2002, 30 (23) : 5160 - 5167
  • [5] COWSERT LM, 1999, Patent No. 5945290
  • [6] Antisense therapeutics: lessons from early clinical trials
    Flaherty, KT
    Stevenson, JP
    O'Dwyer, PJ
    [J]. CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) : 499 - 505
  • [7] Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
    Ho, SP
    Bao, YJ
    Lesher, T
    Malhotra, R
    Ma, LY
    Fluharty, SJ
    Sakai, RR
    [J]. NATURE BIOTECHNOLOGY, 1998, 16 (01) : 59 - 63
  • [8] A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes:: correlation with an intracellular pattern and known RNA structures
    Matveeva, O
    Felden, B
    Audlin, S
    Gesteland, RF
    Atkins, JF
    [J]. NUCLEIC ACIDS RESEARCH, 1997, 25 (24) : 5010 - 5016
  • [9] Prediction of antisense oligonucleotide efficacy by in vitro methods
    Matveeva, O
    Felden, B
    Tsodikov, A
    Johnston, J
    Monia, BP
    Atkins, JF
    Gesteland, RF
    Freier, SM
    [J]. NATURE BIOTECHNOLOGY, 1998, 16 (13) : 1374 - 1375
  • [10] Gene silencing in mammals by small interfering RNAs
    McManus, MT
    Sharp, PA
    [J]. NATURE REVIEWS GENETICS, 2002, 3 (10) : 737 - 747